At the request of the exchanges, the U.S./Hong Kong stock quotes are displayed on a 15-minute delay, download the APP to view the real-time quotes for free.
Close
02105 LAEKNA-B
Closed 11-15 16:08:33
11.140
+0.080
+0.72%
High12.000
Low10.900
Vol6.23M
Open11.300
D1 Closing11.060
Amplitude9.95%
Mkt Cap4.35B
Tradable Cap4.35B
Total Shares390.10M
T/O70.76M
T/O Rate1.60%
Tradable Shares390.10M
P/B--
ROE--
EPS0.00
52wk High--
52wk Low--
P/E--
Dividend--
Div.Yield--
ROA--
Disclaimer: HKEx Information Services Limited, its holding companies and/or any subsidiaries of such holding companies endeavour to ensure the accuracy and reliability of the information provided, but do not guarantee its absolute accuracy and reliability and accept no liability (whether in tort or contract or otherwise) for any loss or damage arising from any inaccuracies or omissions.
Stock Track | Laekna Soars as Obesity Drug Shows Promise in Clinical Trials
Laekna Inc is an investment holding company mainly engaged in the discovery, development and commercialization of innovative therapies for cancer and liver disease. The Company is mainly engaged in the research and development of drug candidates for monotherapy and combination therapy, focusing on the treatment of various cancers and liver fibrosis diseases. The Company's main product pipelines include LAE002 and LAE001. The LAE002 is an adenosine triphosphate (ATP) competitive AKT inhibitor for the treatment of ovarian cancer, prostate cancer, breast cancer and PD-1/PD-L1 drug-resistant solid tumors. The LAE001 is an androgen synthesis inhibitor that simultaneously inhibits cytochrome P450 family 17 subfamily A member 1 (CYP17A1) and cytochrome P450 family 11 subfamily B member 2 (CYP11B2) for the treatment of prostate cancer. The Company mainly conducts its businesses in China, the United States, Europe and South Korea.